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From January l, 1946, through January I, 1986, at the University of Michigan, 60 patients 
were treated with Stage IB (FIGO) carcinoma of the cervix with lymph node metastases. 
Clinical variables were examined with regard to long-term survival. Prognostically significant 
variables were (1) highest level of lymph node involvement and (2) tumor histology. Patients 
with common iliac or periaortic node involvement had an actuarial survival at 5 years of 
14%; 5-year survival for patients with only pelvic node involvement (external iliac, hypogastric, 
or obturator) was 68%. Patients with adenocarcinoma or adenosquamous histology had an 
actuarial survival at 5 years of 16%; 5-year survival for patient with squamous cell carcinoma 
was 71%. Overall survival for all patients with lymph node involvement was 61%. For 
patients undergoing radical hysterectomy as primary treatment, postoperative adjuvant 
radiotherapy did not significantly improve survival. © 1988 Academic Press, Inc. 
INTRODUCTION 
Regional lymph node involvement has a significant impact upon survival in 
Stage IB (FIGO) carcinoma of the cervix. Overall 5-year survival for Stage IB 
carcinoma of the cervix is presently 80 to 90% [1]. When lymph node metastases 
are present, however, long-term survival falls to less than 60% [2]. The present 
study was undertaken to review the clinical factors affecting survival among 
those patients with Stage IB carcinoma of the cervix with lymph node metastases. 
MATERIALS AND METHODS 
During the period January l, 1946, through January l, 1986, 362 patients 
underwent radical hysterectomy and pelvic lymphadenectomy at the University 
of Michigan Medical Center for Stage IB carcinoma of the cervix. Forty-seven 
patients (13%) were found to have lymph node metastases. Eleven patients with 
Stage IB cervical carcinoma had lymph node metastases documented at the time 
of exploratory laparotomy. These patients were found to have fixed or confluent 
nodes judged to be unresectable; biopsies were done to confirm metastatic tumor. 
One patient had nodal metastases noted on pretreatment lymphangiogram and 
confirmed by fine-needle aspiration. One patient underwent an extrafascial hys- 
terectomy and selective lymph node biopsies for a preoperative diagnosis of 
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TABLE 1 
TUMOR HISTOLOGY IN RELATION TO HIGHEST LEVEL OF LYMPH NODE INVOLVEMENT 
Squamons cell 
carcinoma Adenocarcinoma" Total 
Pelvic (obturator, 
hypogastric, external iliac) 43 10 53 
Common i!iac 2 0 2 
Periaortic 2 3 5 
Total 47 13 60 
a Including adenosquamous. 
adenocarcinoma of the endometrium; the surgical specimen revealed a primary 
endocervical adenocarcinoma with lymph node metastases. There were, therefore, 
60 patients available for review with Stage IB carcinoma of the cervix with lymph 
node metastases. 
The ages of the patients ranged from 20 to 76 with a mean age of 41. There 
were 13 patients with adenocarcinoma or adenosquamous carcinoma and 47 
patients with squamous cell carcinoma. Two patients (3%) had extension to the 
level of the common iliac node group; 5 patients (8%) had extension up to the 
periaortic node group. Tumor histology in relation to highest level of lymph node 
involvement is indicated in Table 1. The difference in the distributions of the 
highest level of node involvement when stratified by tumor histology is not 
statistically significant. 
All patients underwent primary treatment with curative intent. Forty-seven 
patients underwent radical hysterectomy with pelvic lymphadenectomy. Of these 
47 patients, 20 received postoperative irradiation. Seven patients were treated 
primarily with radiotherapy. Four patients were treated with a combination of 
radiotherapy and chemotherapy. One patient underwent an extrafascial hyster- 
ectomy and postoperative radiotherapy. One patient underwent radiotherapy 
followed by a selective lymph node resection as primary treatment. 
The technique of performing the radical hysterectomy has been previously 
described [1]. Patients undergoing postoperative irradiation received 5000 tad 
megavoltage teletherapy to a pelvic field. Primary radiotherapy was administered 
combining intracavitary sources with external beam irradiation. 
Clinical charts and tumor board recommendations were reviewed to assess 
selection factors in determining which patients undergoing radical hysterectomy 
received postoperative irradiation. The only significant selection factor identified 
was the time period in which patients received treatment. One of 21 patients 
(5%) undergoing treatment prior to 1975 received postoperative irradiation. Nineteen 
of 26 patients (76%) treated after 1975 received postoperative irradiation. This 
difference was statistically significant (P < 0.005 by chi-square analysis). 
Five-year survivals were calculated using the actuarial method of Berkson and 
Gage [3]. Survival distributions were compared using Mantel and Haenszel's chi 
square test [4]. 
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RESULTS 
Overall actuarial survival at 5 years for patients with Stage IB carcinoma of 
the cervix with lymph node involvement was 61%. When only the pelvic nodes 
were involved (external iliac, hypogastric, or obturator), 5-year survival was 
68%. When there was extension to involve the common iliac or periaortic lymph 
nodes, 5-year survival was 14%. This difference was statistically significant (P 
< 0.005). 
Five-year survival in patients with adenocarcinoma or adenosquamous carcinoma 
was 16%; for patients with squamous cell carcinoma 5-year survival was 71%. 
This difference was statistically significant (P < 0.005). The difference in survival 
distributions remained statistically significant even when patients with common 
iliac or periaortic node involvement were excluded from the analysis. 
Histologic grade did not affect survival. Multiplicity of node involvement, i.e., 
metastatic tumor identified in single versus multiple lymph nodes, did not affect 
survival. Also, bilaterality of lymph node involvement did not correlate with 
survival. 
For patients undergoing radical hysterectomy with and without postoperative 
radiotherapy, 5-year survivals were 72 and 64%, respectively. This difference 
was not statistically significant. Five-year survival for patients undergoing primary 
radiotherapy was 43%; when compared to patients undergoing radical hysterectomy, 
this difference was not statistically significant. 
Four patients underwent combined treatment with radiotherapy and chemo- 
therapy. One patient received concurrent treatment with hydroxyurea; the other 
three patients were treated in a sequential manner. The outcome for these patients 
is summarized in Table 2. 
One patient demonstrated metastatic tumor in a right obturator lymph node 
on pretreatment lymphangiogram; this was confirmed by fine-needle aspiration. 
She was treated with 5000 tad four-field external beam irradiation, intracavitary 
cesium, and an additional boost to the right pelvic sidewall. A selective lymph 
node resection was then performed revealing focal residual carcinoma; ipsilateral 
external iliac and common iliac nodes were negative. The patient remains free 
of disease at 19 months. 
Sites of recurrence, stratified by tumor histology, are summarized in Table 3. 
One patient with a pelvic sidewall recurrence survived following radiotherapy; 
all other patients that developed recurrent tumor died of disease. All recurrences 
in patients treated with radical hysterectomy alone had pelvic disease as a com- 
ponent of the recurrence. Recurrences after radical hysterectomy with postoperative 
radiotherapy involved the pelvis less frequently, occurring in only 50% of patients 
with recurrent disease. 
DISCUSSION 
The incidence of lymph node metastases in patients with Stage IB carcinoma 
of the cervix is estimated to be approximately 15% [5]. The present series 
confirms other reports that 5 year survival in this group of patients approximates 
60% [2,6]. In the present series, the two most significant factors affecting survival 
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T A B L E  3 
SITES OF RECURRENCE 
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S quamous  cell 
carc inoma Adenocarc inoma" Total 
Pelvis 4 l 5 
Distant  1 4 5 
Pelvis and distant  7 3 10 
Not  specified 3 0 3 
" Including adenosquamous .  
were (1) the highest level of lymph node involvement and (2) tumor histology. 
Common iliac or periaortic lymph node involvement indicated a poor long-term 
survival. Five-year survival in this group of patients was 14%. Others have 
reported similar survival rates in patients with tumor extension to the common 
iliac or periaortic level [2,7]. Extension to involve this level of nodes can be an 
indication of systemic disease and therefore may not be effectively treated with 
regional therapy. Addition of chemotherapy to the treatment program would 
seem logical in attempting to improve salvage in this group of patients. In the 
present series, three of seven patients with nodes involved at this level underwent 
combined radiotherapy-chemotherapy as primary treatment. All three patients 
died of recurrent disease; two recurred with distant metastases. The development 
of more effective chemotherapeutic agents for carcinoma of the cervix may help 
improve outcome in this group of patients. 
In the present series, the prognosis for patients with Stage IB carcinoma of 
the cervix with lymph node metastases correlated significantly with tumor histology. 
Patients with adenocarcinoma or adenosquamous tumors had an actuarial survival 
at 5 years of 16%, significantly worse than for patients with squamous cell 
carcinoma. Berek et  al. have reported a 10% 5-year survival in patients with 
adenocarcinoma of the cervix with lymph node metastases [8]. In the present 
study, seven of eight patients with recurrent adenocarcinoma had distant metastases 
as a component of recurrence. This confirms Berek's impression that lymph node 
involvement with adenocarcinoma of the cervix often indicates systemic disease 
[8]. Logically, consideration should be given to treating these patients with 
chemotherapy. Clearly, additional clinical trials are needed in this area. 
In the present study the addition of postoperative radiotherapy did not improve 
survival in patients undergoing radical hysterectomy and pelvic lymphadenectomy. 
Restrospectively, there was no significant difference in the clinical characteristics 
between the two groups other than the time period of treatment. It appears that 
recently a greater proportion of patients treated at the University of Michigan 
received adjunctive radiotherapy for positive lymph nodes; the reason for this 
trend is unclear. Morrow, reporting on a collective series of 174 patients with 
Stage IB cervical carcinoma with pelvic node metastases was also unable to 
demonstrate any significant improvement in survival for patients undergoing 
postoperative radiotherapy [6]. Martimbeau, although unable to demonstrate an 
improved survival in such patients, recommends postoperative adjunctive ra- 
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diotherapy since it is difficult to completely resect all of the pelvic lymphatics 
[2]. In the present series, postoperative radiotherapy appeared to improve regional 
tumor control; this did not correlate with a significant improvement in long-term 
survival, however. 
There were seven patients in the study treated with primary radiotherapy. 
Although survival in this group was lower (43% at 5 years), the difference was 
not statistically significant, suggesting that treatment modality was not a primary 
determinant of survival. Furthermore, the lower survival reflects the selection 
bias of patients treated with radiotherapy in this series. Three patients had 
common iliac or periaortic node involvement and four patients had fixed, confluent 
pelvic node involvement. Clearly, then, radiotherapy can effectively sterilize 
regional lymphatics, occasionally even when tumor involvement is extensive. 
This confirms the impression of others [2,9] and indicates a role for radiotherapy 
in the primary treatment of  such individuals. 
Of interest in this regard is the single patient who had nodal metastases indentified 
by pretreatment lymphangiogram. The use of noninvasive imaging techniques 
when combined with fine-needle aspiration may be useful in identifying patients 
with regional node involvement [10,11]. Treatment can then be individualized 
based on the documented extent of disease. 
In summary, the overall survival for patients with Stage IB carcinoma of the 
cervix with lymph node metastases is 61%. Patients with tumor extension to the 
common iliac or periaortic nodes are at particularly high risk for recurrence. 
Patients with adenocarcinoma or adenosquamous histology, regardless of level 
of node involvement, are also at high risk for recurrence. Further investigation 
needs to be carried out to improve salvage in these high risk groups. Radiotherapy 
can effectively treat patients with regional lymphatic involvement; noninvasive 
imaging studies may be useful adjuncts in identifying such individuals. 
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